Title : Anti-NMDA receptor encephalitis in a patient with Ankylosing Spondylitis receiving etanercept treatment
Abstract:
A patient diagnosed with Ankylosing Spondylitis on long-term etanercept treatment presented in the Emergency Department with subacute progressive cognitive dysfunction and personality change. He further developed psychiatric symptoms, autonomic dysfunction and orofacial dyskinesias within the first days of admission. His serum was initially negative for autoimmune neuronal antibodies, however CSF analysis was positive for anti-N-Methyl-D-Aspartate Receptor (anti-NMDAR). During his ten-week admission, he was treated with intravenous methylprednisolone, intravenous immunoglobulins, plasma exchange and rituximab before making full recovery with minimal residual neurological deficits. He was discharged on a weaning dose of oral prednisolone, however was re-admitted two months later with pneumocystis jirovecii pneumonia and required three weeks inpatient treatment with intravenous antibiotics. To our knowledge, this is the first report of etanercept-associated anti-NMDAR encephalitis. This case additionally highlights the importance of CSF over serum sampling in suspected anti-NMDAR encephalitis and serves as a reminder for clinicians to consider prophylaxis against pneumocystis pneumonia (PCP) when using long-term corticosteroids for neurological conditions